KN-01 is under clinical development by PendreaBio and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KN-01 (Ceramide NanoLiposome) is under development for the treatment of Rrelapsed and refractory acute myeloid leukemia (RR-AML), solid tumors including liver cancer, pancreatic cancer, androgen receptor negative prostate cancer and breast cancer. It is administered intravenously. The drug candidate is a liposomal formulation of ceramide. It is developed based on nanoLiposome technology.
PendreaBio formerly Keystone Nano, is a healthcare service provider that manufactures and markets nanoscale products to chemicals and pharmaceuticals companies. The center offers nanoparticle surfaces with passive and active targeting strategies. Its products are used for the treatment of solid-tumor and non-solid-tumor cancers, chemical research, diagnostic imaging and biological investigations, among others. PendreaBio’s NanoJacket and NanoLiposomes technologies supports to improve the delivery of chemicals and pharmaceuticals. The center also caters to medical, scientific and industrial sectors. It partners with pharmaceutical, biotechnology companies and cancer institutions, among others. PendreaBio is headquartered in State College, Pennsylvania, the US.
For a complete picture of KN-01’s drug-specific PTSR and LoA scores, buy the report here.